Anhui Fengyuan Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	7.8yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

May 07

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Apr 17

CEO

Anhui Fengyuan Pharmaceutical no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jun Li	Financial Director	7.2yrs	CN¥398.00k	0.12% CN¥ 3.5m
Shaoyi Zhang	Deputy GM & Director	17.1yrs	CN¥576.00k	0.090% CN¥ 2.7m
Zhenhong Lu	Deputy GM & Director	3.7yrs	CN¥462.00k	0.11% CN¥ 3.1m
Tianle Ru	GM & Director	8.3yrs	CN¥684.00k	0.30% CN¥ 9.0m
Jinchao Duan	Deputy GM & Director	4.9yrs	CN¥324.00k	0.060% CN¥ 1.8m
Jun Zhang	Secretary of the Board & Non-Independent Director	25.6yrs	CN¥330.00k	0.14% CN¥ 4.0m
Guo Kun Li	Deputy General Manager	11.1yrs	CN¥386.00k	0.060% CN¥ 1.8m
Shuang Qing Yin	Deputy General Manager	4.9yrs	CN¥368.00k	0.090% CN¥ 2.7m

7.8yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000153 es experimentado (7.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shaoyi Zhang	Deputy GM & Director	9.6yrs	CN¥576.00k	0.090% CN¥ 2.7m
Zhenhong Lu	Deputy GM & Director	8.2yrs	CN¥462.00k	0.11% CN¥ 3.1m
Tianle Ru	GM & Director	1.8yrs	CN¥684.00k	0.30% CN¥ 9.0m
Jinchao Duan	Deputy GM & Director	1.8yrs	CN¥324.00k	0.060% CN¥ 1.8m
Jun Zhang	Secretary of the Board & Non-Independent Director	4yrs	CN¥330.00k	0.14% CN¥ 4.0m
Hongman He	Chairman of the Board	16.2yrs	CN¥760.00k	0.45% CN¥ 13.5m
Yue'e Hu	Chairman of Supervisory Board	1.8yrs	CN¥420.00k	sin datos
Weidong Zhu	Independent Director	4.9yrs	CN¥60.00k	sin datos
Jiemiao Chen	Independent Director	4.9yrs	CN¥60.00k	sin datos
Jinsheng Hu	Non-Employee Supervisor	4.9yrs	sin datos	sin datos
Cisheng Wu	Independent Director	1.8yrs	CN¥30.00k	sin datos
Hui Yan Sun	Supervisor	4.9yrs	sin datos	sin datos

4.9yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 000153 se considera experimentada (4.8 años de antigüedad promedio).

Anhui Fengyuan Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

High number of new directors

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

High number of new and inexperienced directors

Recent updates

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for 2023

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.14 in 1Q 2023)

Now 23% overvalued

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 2Q 2022)

Anhui Fengyuan Pharmaceutical Announces Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.37 in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 2Q 2021)

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022

Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Distribution for 2021

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.041 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.26 in FY 2019)

Investor sentiment improved over the past week

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥6.62

Investor sentiment deteriorated over the past week

New 90-day low: CN¥7.79

New 90-day low: CN¥8.07

New 90-day low: CN¥8.22

Third quarter earnings released

First half earnings released

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥12.49

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad